Back to Search Start Over

Oncology Navigation Decreases Time to Treatment in Patients with Pancreatic Malignancy

Authors :
Boris Pasche
Clancy J. Clark
A. William Blackstock
Russell Howerton
Perry Shen
Joyce Fenstermaker
Rodwige J. Desnoyers
Edward A. Levine
Laura M. Enomoto
Source :
Annals of Surgical Oncology. 26:1512-1518
Publication Year :
2019
Publisher :
Springer Science and Business Media LLC, 2019.

Abstract

Care of pancreatic cancer patients has become increasingly complex, which has led to delays in the initiation of therapy. Nurse navigators have been added to care teams, in part, to ameliorate this delay. This study investigated the difference in time from first oncology visit to first treatment date in patients with any pancreatic malignancy before and after the addition of an Oncology Navigator. A single-institution database of patients with any pancreatic neoplasm evaluated by a provider in radiation, medical, or surgical oncology between 1 October 2015 and 30 September 2017 was analyzed. After 1 October 2016, an Oncology Navigator met patients at their initial visit and coordinated care throughout treatment. The cohort was divided into two groups: patients evaluated prior to the implementation of an Oncology Navigator and patients evaluated after implementation. Patient demographics and time from first visit to first intervention were compared. Overall, 147 patients with a new diagnosis of pancreatic neoplasm were evaluated; 57 patients were seen prior to the start of the Oncology Navigator program and 79 were evaluated after the navigation program was implemented. On univariate analysis, time from first contact by any provider to intervention was 46 days prior to oncology navigation and 26 days after implementation of oncology navigation (p = 0.005). While controlling for other covariates, employment of the Oncology Navigator decreased the time from first contact by any provider to intervention by almost 16 days (p = 0.009). Implementing an oncology navigation program significantly decreased time to treatment in patients with pancreatic malignancy.

Details

ISSN :
15344681 and 10689265
Volume :
26
Database :
OpenAIRE
Journal :
Annals of Surgical Oncology
Accession number :
edsair.doi.dedup.....9c33879324f772d7e4a14a1d3026a698
Full Text :
https://doi.org/10.1245/s10434-019-07157-6